Preclinical research demonstrates that MCC950 can cross the BBB via intraperitoneal (i.p.)or intranasal administration, lowering IL-1β and IL-18 concentrations in the hippocampus and amygdala and improving behavioral outcomes in chronic stress and PTSD models. This evidence concerns the gene IL1B and post-traumatic stress disorder.